Gene Vector Technologies

Gene Vector Technologies (GVT) is a research-driven biotechnology company focused on the development of advanced viral vector platforms for vaccines and therapeutics. The company specializes in the use of alphavirus-based vectors and virus-like particles (VLPs) to address emerging infectious diseases and biodefense threats. Their proprietary technology focuses on creating highly immunogenic candidates for indications such as influenza, Zika virus, and viral hemorrhagic fevers. GVT operates primarily through strategic collaborations and significant non-dilutive funding from U.S. federal agencies, including the National Institutes of Health (NIH) and the Department of Defense (DOD). The company's expertise spans molecular virology, recombinant DNA technology, and vaccine formulation. Based in Maryland, GVT continues to advance its preclinical pipeline toward clinical validation of its modular vaccine delivery systems.